Alpine Global Management’s Palvella Therapeutics PVLA Stock Holding History

Alpine Global Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-135	Closed	-$33	–	661
2022 Q1	$33	Sell	135 -840	-86%	-$221K	0.01%	330
2021 Q4	$295K	Buy	+975	New	+$312K	0.04%	439
2021 Q3	–	Sell	-135	Closed	-$41K	–	385
2021 Q2	$41K	Buy	+135	New	+$29.6K	0.01%	287
2020 Q1	–	Sell	-250	Closed	-$72K	–	461
2019 Q4	$72K	Sell	250 -290	-54%	-$80.4K	0.02%	375
2019 Q3	$147K	Sell	540 -23	-4%	-$8.9K	0.04%	70
2019 Q2	$212K	Hold	563	–	–	0.06%	55
2019 Q1	$151K	Sell	563 -101	-15%	-$24K	0.04%	76
2018 Q4	$141K	Buy	664 +101	+18%	+$31.3K	0.04%	197
2018 Q3	$252K	Hold	563	–	–	0.05%	71
2018 Q2	$228K	Buy	563 +313	+125%	+$149K	0.11%	52
2018 Q1	$136K	Buy	+250	New	+$155K	0.03%	92

Other funds holding PVLA

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alpine Global Management's PVLA Position: Q2 2022 in Review

Alpine Global Management sold out of Palvella Therapeutics (PVLA) in Q2 2022, closing a stake of 135 shares — an estimated $33 sold.

Alpine Global Management first reported a position in PVLA in Q1 2018 and held it in 11 quarters. The position peaked at $295K in Q4 2021. 68 funds tracked by Wall St. Rank hold PVLA as of Q2 2022.

Alpine Global Management reported no remaining Palvella Therapeutics position as of Q2 2022 after selling out during the quarter.
Alpine Global Management sold 135 Palvella Therapeutics shares in Q2 2022, an estimated $33.
Alpine Global Management first reported a position in Palvella Therapeutics in Q1 2018 and held it in 11 quarters.
Alpine Global Management's Palvella Therapeutics position peaked at $295K in Q4 2021.
68 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2022.

Based on Alpine Global Management's 13F filing for Q2 2022, filed 15 Aug 2022.